BioAlliance Launches Loramyc in the UK, Germany and Denmark

BioAlliance Pharma, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced the launch of its lead product Loramyc on the British, German and Danish markets.
MarketWatch